Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%.

The overhaul, unveiled Tuesday, is designed to reduce bluebird’s cash operating expenses by about 20% and to help the company break even on quarterly cash flows in the second half of 2025.